Orlistat
Safety and Efficacy of Xenical in Children and Adolescents With Obesity-Related Diseases
Empros Pharma AB · Phase 2 · Completed · Enrollment 200
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Placebo | 9 participants | 7 participants | 8 participants | n/r | n/r |
| Orlistat | 10 participants | 7 participants | 21 participants | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.